Literature DB >> 32857612

CD38 as an immunomodulator in cancer.

Yanli Li1, Rui Yang1, Limo Chen2, Sufang Wu1.   

Abstract

CD38 is a transmembrane glycoprotein that is widely expressed in a variety of human tissues and cells, especially those in the immune system. CD38 protein was previously considered as a cell activation marker, and today monoclonal antibodies targeting CD38 have witnessed great achievements in multiple myeloma and promoted researchers to conduct research on other tumors. In this review, we provide a wide-ranging review of the biology and function of the human molecule outside the field of myeloma. We focus mainly on current research findings to summarize and update the findings gathered from diverse areas of study. Based on these findings, we attempt to extend the role of CD38 in the context of therapy of solid tumors and expand the role of the molecule from a simple marker to an immunomodulator.

Entities:  

Keywords:  CD38; biomarker; cancer immunotherapy; immune checkpoint therapy; immunomodulation; tumor microenvironment

Year:  2020        PMID: 32857612     DOI: 10.2217/fon-2020-0401

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  3 in total

Review 1.  Targeting CD38 in Neoplasms and Non-Cancer Diseases.

Authors:  Wojciech Szlasa; Jakub Czarny; Natalia Sauer; Katarzyna Rakoczy; Natalia Szymańska; Jakub Stecko; Maksymilian Kołodziej; Maciej Kaźmierczak; Ewa Barg
Journal:  Cancers (Basel)       Date:  2022-08-28       Impact factor: 6.575

2.  Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study.

Authors:  Paolo Andrea Zucali; Chia-Chi Lin; Bradley C Carthon; Todd M Bauer; Marcello Tucci; Antoine Italiano; Roberto Iacovelli; Wu-Chou Su; Christophe Massard; Mansoor Saleh; Gennaro Daniele; Alastair Greystoke; Martin Gutierrez; Shubham Pant; Ying-Chun Shen; Matteo Perrino; Robin Meng; Giovanni Abbadessa; Helen Lee; Yingwen Dong; Marielle Chiron; Rui Wang; Laure Loumagne; Lucie Lépine; Johann de Bono
Journal:  J Immunother Cancer       Date:  2022-01       Impact factor: 13.751

3.  Systemic Immune Dysregulation Correlates With Clinical Features of Early Non-Small Cell Lung Cancer.

Authors:  Zhixing Hao; Mingjie Lin; Feng Du; Zhongwei Xin; Dang Wu; Qun Yu; Yimin Wu; Zhouyu Zhu; Wenshan Li; Yongyuan Chen; Xiaoke Chen; Ying Chai; Shenghang Jin; Pin Wu
Journal:  Front Immunol       Date:  2022-01-18       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.